FIRE-3 — FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First-Line KRAS Wild-Type Metastatic Colorectal Cancer

Phase 3 · 2014 · Colorectal Cancer

Design

Randomized FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab as first-line therapy.

Population

KRAS (later RAS) wild-type metastatic colorectal cancer.

Primary Endpoint

objective response rate

Key Result

Similar response and PFS, but overall survival favored cetuximab (33.1 vs 25.0 mo in RAS wild-type), and the data helped reveal the importance of primary tumor sidedness.

Guideline Impact

Informs anti-EGFR use and tumor-sidedness guidance in first-line mCRC